SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of the antibody response in relation to the outcome we performed a study in hospitalized COVID-19 patients. As comparison we also investigated the time course of the antibody response in SARS-CoV-2 asymptomatic subjects. Study results show that patients produce a strong antibody response to SARS-CoV-2 with high correlation between different viral antigens (spike protein and nucleoprotein) and among antibody classes (IgA, IgG, and IgM and neutralizing antibodies). The antibody peak is reached by 3 weeks from hospital admission followed by a sharp decrease. No difference was observed in any parameter of the antibody classes, including neutralizing antibodies, between subjects who recovered or with fatal outcome. Only few asymptomatic subjects developed antibodies at detectable levels.

Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection / S. Marchi, S. Viviani, E.J. Remarque, A. Ruello, E. Bombardieri, V. Bollati, G.P. Milani, A. Manenti, G. Lapini, A. Rebuffat, E. Montomoli, C.M. Trombetta. - In: PLOS ONE. - ISSN 1932-6203. - 16:7(2021), pp. e0253977.1-e0253977.18. [10.1371/journal.pone.0253977]

Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection

V. Bollati;G.P. Milani;
2021

Abstract

SARS-CoV-2 pandemic is causing high morbidity and mortality burden worldwide with unprecedented strain on health care systems. To investigate the time course of the antibody response in relation to the outcome we performed a study in hospitalized COVID-19 patients. As comparison we also investigated the time course of the antibody response in SARS-CoV-2 asymptomatic subjects. Study results show that patients produce a strong antibody response to SARS-CoV-2 with high correlation between different viral antigens (spike protein and nucleoprotein) and among antibody classes (IgA, IgG, and IgM and neutralizing antibodies). The antibody peak is reached by 3 weeks from hospital admission followed by a sharp decrease. No difference was observed in any parameter of the antibody classes, including neutralizing antibodies, between subjects who recovered or with fatal outcome. Only few asymptomatic subjects developed antibodies at detectable levels.
Settore MEDS-10/B - Malattie infettive
2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
journal.pone.0253977.pdf

accesso aperto

Descrizione: Research Article
Tipologia: Publisher's version/PDF
Dimensione 2.34 MB
Formato Adobe PDF
2.34 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1163101
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 35
  • OpenAlex ND
social impact